Zsírmáj (MASLD/MASH): vizsgálatok itt: Japán
10 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Where
- Kawasaki-shi, Ōgaki
- Életkor
- 18 év to 75 év
- People
- 1740 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07701993 - 3. fázisTaking peopleA Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Where
- Kawasaki-shi, Ōgaki
- Életkor
- 18 év to 75 év
- People
- 380 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07704892 - 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Bunkyō City, Chiba, Chiba, Ichikawa, Ehime, Toon, Fukui-shi, Fukuoka, Fukuoka, Fukuoka, Kurume, Gifu, Gifu, Hanishina-gun, Hiroshima, Hokkaido, Sapporo, Hyogo, Nishinomiya, Ibaraki, Inashiki-gun, Isehara-Shi, Ishikawa, Kanazawa, Izumo, Kagoshima, Kanagawa, Kawasaki, Kawasaki-shi, Kita-gun, Kobe, Kumamoto, Kure, Kyoto, Miyazaki, Musashino, Nagano, Matsumoto, Nagasaki, Omura, Nara, Kashihara, Narita, Niigata, Ōita, Okayama, Osaka, Saga, Sakai, Sapporo, Sendai, Shimonoseki, Shiwa-gun, Shizuoka, Hamamatsu, Shizuoka, Izunokuni, Suita-shi, Suita-Shi, Takasaki-shi, Tokyo, Tokyo, Bunkyo-ku, Tokyo, Minato-ku, Toyoake-shi, Tsu, Wakayama, Yokohama
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Bunkyō City, Chiba, Ehime, Toon, Fukui-shi, Fukuoka, Fukuoka, Fukuoka, Kurume, Gifu, Gifu, Gifu, Ogaki, Hanishina-gun, Hiroshima, Hokkaido, Sapporo, Ibaraki, Inashiki-gun, Isehara-Shi, Ishikawa, Kanazawa, Izumo, Kagoshima, Kanagawa, Kawasaki, Kita-gun, Kobe, Kumamoto, Kure, Kyoto, Miyazaki, Musashino, Nagano, Matsumoto, Nagasaki, Omura, Nara, Kashihara, Narita, Niigata, Nishinomiya, Ōita, Okayama, Osaka, Saga, Sakai, Sapporo, Sendai, Shiwa-gun, Shizuoka, Hamamatsu, Shizuoka, Izunokuni, Suita-shi, Suita-Shi, Takasaki-shi, Tokyo, Tokyo, Bunkyo-ku, Tokyo, Minato-ku, Toyoake-shi, Tsu, Wakayama, Yokohama
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Ehime, Fukuoka, Gifu, Hizume, Kawasaki, Kumamoto, Maebashi, Nagano, Okayama, Osaka, Saga, Sapporo, Yokohama
- Életkor
- 18 év to 80 év
- People
- 1350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - 3. fázisTaking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Bunkyō-Ku, Fukui-shi, Kyoto, Maebashi, Minato-Ku, Musashino, Ōgaki, Shinjuku, Suita-shi, Wakayama, Yokohama
- Életkor
- 18 év to 80 év
- People
- 2150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - 2. fázisTaking peopleA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Where
- Sapporo
- Életkor
- 18 év to 75 év
- People
- 120 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05519475 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Amagasaki, Asahikawa, Bunkyō, Bunkyō City, Chikushino-shi, Fukuoka, Gifu, Ginowan, Hamamatsu, Hiroshima, Ichikawa, Izumo, Izunokuni, Kagoshima, Kashihara, Kawasaki, Kita-ku, Kofu, Kumamoto, Kurume, Kyoto, Maebashi, Minatoku, Musashino-shi, Nagasaki, Nagoya, Narita, Nishinomiya, Ōgaki, Ōita, Okayama, Ōmura, Osaka, Saga, Sakai, Sapporo, Shimotsuke, Shinjuku-ku, Shinjyuku-ku, Shiwa-gun Yahaba-cho, Suita, tabashi City, Takamatsu, Takasaki, Tokyo, Tomitake, Tōon, Toshimaku, Tsu, Ureshino, Yamagata, Yokohama
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - 3. fázisTaking peopleA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Gunma, Kagoshima
- Életkor
- 18 év to 75 év
- People
- 1250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00 - 3. fázisTaking peopleA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- Where
- Gifu, Kanagawa, Kyoto, Musashino, Yokohama
- Életkor
- 18 év to 75 év
- People
- 1200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221227